Late last month, on the Sean Spicer show, Patrick Soon-Shiong said a few things that set off a reaction we could not shake. A few days ago we sized the first of them in the Gulf: what this drug could be worth if it were approved to rebuild the immune system itself, in cancer and in sepsis. The number came back big enough that we could not stop there. A PLAN HIDING IN PLAIN SIGHT Because this is not one drug, or one region, and what he floated on that show was not even new. The lymphopenia and sepsis he described are just two pieces of something far bigger that he had put on the record months earlier, in plain sight, and that almost everyone forgot. So take the tour back to this past February, when ImmunityBio spelled the whole thing out in a detailed press release: a three-year expansion plan for what it calls its Cancer BioShield platform. It is not modest: more than thirty active and planned trials across ten tumor types, gone after one by one. And running under all of it is the very thing this drug is built to reverse, the collapse of the immune system itself, which is what lymphopenia and sepsis are. Run it to the end and you are not looking at a small biotech anymore. You are looking at what this company could grow into over one, three, five, ten, twenty, thirty years. FOUR POSTS, EACH BIGGER THAN THE LAST So we are doing something here we have not done before: a series of four posts, each one covering more ground than the last, with the full math shown at every step so you can check us. The first post, a few days ago, sized the Gulf. This second post, today, is America, the biggest drug market on earth: what lymphopenia and sepsis alone could be worth here, the number a few of you asked for. The third post will go global and add every cancer in the three-year plan, the whole world in a single pass. And the fourth post will ask the wild question almost no one says out loud: whether a drug that rebuilds the immune system could break the ceiling on what a single company is allowed to become, an Nvidia of biotech. The numbers start sober in this post and end staggering by the fourth, and we will not hide a single step in between. WHY AMERICA, AND THE BETS WE NAME We continue with America, because it holds the biggest prize in the plan, and the slowest door to it. And here is the honest deal for this one, so nobody feels sold to. On the things we can hold down, we hold them all the way down: net prices, not the sticker; a single country, when the drug is already sold in dozens more; a modest share of patients, not all of them. But two dials we are not going to hide, because they are the bet: that this spreads fast, the way a survival drug spreads, and that it keeps its price the way survival drugs do. We name the bet and let you watch it in daylight. If you think either one goes the other way, we hand you the dial to turn it down yourself. THE CLOCK HAS NOT EVEN STARTED And hold one thing in your mind the whole way down, because we will keep saying it: none of this is approved yet. Not the lymphopenia use, not the sepsis use, nowhere on earth. Every number below is the size of a prize that opens only if and when those approvals come. So when you read Year 1, it does not mean next year. It means the first year after an approval that has not happened, and may never. FIRST, THE SAME TWO DOORS The idea is the one we walked in the Gulf, so we will keep it short. Your lymphocytes, chiefly your T cells and your natural killer cells, are the standing army of your immune system. Lymphopenia is that army falling below fighting strength. It happens to two large groups of very sick people: cancer patients whose chemotherapy and radiation burn down their own immune ranks, and sepsis patients whose bodies are overrun by infection. A missing immune army is one of the strongest danger signs in medicine: these patients catch more infections, and they die sooner. ANKTIVA is built to rebuild that count. In America, both of those groups are enormous. COUNT THE FALLEN Let us count them the way we count everything here, one honest funnel, real numbers at every step. America diagnoses about two million serious cancers a year, setting aside the common skin cancers that are usually just cut out. Walk the funnel: - Of those two million, roughly two in three are treated with chemotherapy or radiation, the treatments that thin the immune ranks. That is about 1.3 million - Of those, somewhere between half and two thirds see their lymphocyte count fall below strength. That leaves about 800,000 people a year One honest note on that 800,000, because it matters. Today the drug's early-access program admits only the worst hit, the severely lymphopenic, and that gated group is a smaller slice of the pool, closer to 400,000 people a year. The 800,000 is the fuller population a broad approval could reach, because a low immune count harms at every grade and this drug rebuilds it regardless of how far it fell. So read 800,000 as the market at a wide label, and 400,000 as the floor beneath it. That is the first door. The second is sepsis, and in America it is just as wide: about 1.7 million cases a year, of whom around half go lymphopenic. Another 850,000 people. Hold the total for a second. Well over a million and a half Americans a year, their immune armies on the floor, exactly the people this drug was built to put back on their feet. NOW, IS A NUMBER THAT BIG EVEN REAL? In America a course of ANKTIVA lists at about 322,000 dollars, because the United States pays more for its medicines than anywhere on earth. So the tempting move is to multiply: - 800,000 patients a year, - times 322,000 dollars a course = about 258 billion dollars, if every last one were treated, - times even a fifteen percent share, roughly one in seven who actually get it = about 39 billion dollars a year. Thirty-nine billion, from one indication, in one country. That would stand a single lymphopenia add-on beside Keytruda, the best-selling drug in the world today. So is a number that big actually real, or does it fall apart the moment you look closely? You cannot answer that by picking a percentage that feels honest and multiplying. You answer it with three questions, and every one has a real, famous drug standing behind it: how fast does something like this get adopted, what actually happens to the price, and how does the money build over the years. Take them in order. QUESTION #1 - HOW FAST DOES IT SPREAD? A drug like this rolls out one of two ways, and history has run both. The slow way is G-CSF, the drug given to chemo patients whose neutrophils, a different immune cell, collapse. It is the closest cousin a lymphopenia drug has: supportive care for a wrecked blood count, and it prevents a real and deadly complication, not just a bad lab value. It still took about fifteen years to reach most of the patients who needed it, and only got there once the cancer guidelines ordered doctors to use it above a set risk line. It became a five-to-six-billion-dollar franchise. Slowly, and only after a rule pulled it through. The fast way is Keytruda. It reached more than half the patients in a new cancer setting in two to three years, because it does the one thing every patient and doctor is desperate for: it makes people live longer. Nobody waits for a committee to use a drug that saves lives. Survival drags a drug through the door. THE SURVIVAL BET So which is ANKTIVA for lymphopenia? Here is the tell, stated carefully. In its cancer trials, the patients whose immune counts recovered lived markedly longer than those whose counts stayed down. That is a striking signal, and it won an RMAT designation from the FDA in early 2025, the FDA's status for promising early evidence against a serious unmet need. But an honest read has to add the caveat in the same breath: that signal comes from single-arm studies, not yet a randomized trial, so part of it could be that healthier patients recover their counts rather than the drug itself buying the time. The randomized lung-cancer survival trial that would prove cause is still enrolling. So this is the bet, in the open: if the survival benefit holds up, this spreads like Keytruda, not like G-CSF, and we model it that way. If you think the data will disappoint, turn the dial toward the slow curve. QUESTION #2 - WHAT ABOUT THE PRICE? Two fears hide in that question. That a drug this broad must be sold cheap. And that America will force the price down anyway. Both point the same way, and it is not the way you would guess. Start with what the drug is worth. This is not something that fixes a number on a lab chart. Its case is survival, and the drugs that carry a survival benefit sit at the very top of the market. Keytruda is estimated to collect roughly 120,000 dollars a year in net revenue per treated patient after rebates, off a list price now above 200,000. ANKTIVA itself already lists at 322,000 for bladder cancer. So the honest expectation is not that the price collapses to some supportive-care bargain. It is that the price stays high, because of what it does. So for the math ahead we use a net price near 120,000 dollars a year, roughly what a survival drug like Keytruda is estimated to collect once the rebates are stripped out, not the 322,000 list, because a list price is what a drug is billed at, never what a payer really pays. What actually limits the money is not the price, it is the budget. Treating all 800,000 patients at the full 322,000 sticker would run to 258 billion dollars a year, and no health system on earth writes a check like that. So the drug gets rationed to the patients where the evidence is strongest and the need is greatest. High price, and for years a narrow slice of the people who could use it. That is the real shape of the early curve. WHY THE PRICE MATTERS LESS THAN IT SEEMS Here is the part worth sitting with, because it is the answer to the first fear. The health system will spend roughly a fixed amount on this problem, and that amount is the revenue. Deliver it as a high price to a narrow group, or a lower price to a broad group, and the money lands in a similar band. Price times patients is anchored to what the budget will bear, and that anchor is far harder for politics to move than the price alone. Which is exactly why what companies actually do is hold the price. Keytruda launched near 150,000 dollars a year in 2014, nudged its list price up a little almost every year since, and never once cut it, all the way to 30 billion in sales; it grew on volume, not discounts, and still collects an estimated 120,000 net per patient today. In rich markets a price like this only falls years later, when a copycat forces it. WON'T WASHINGTON FORCE IT DOWN? Now the second fear, and it is real: Trump is pushing hard to drag American prices down toward what Europe pays. Medicare has already set a fresh round of negotiated prices on big cancer drugs, cuts of 40 to 60 percent on Xtandi, Ibrance and Pomalyst, effective 2027. But here is the part almost nobody knows. Keytruda, the biggest drug of all, was never even in that round; it was always slated for a later cycle, and a change in the law last year pushed its negotiated price back a further year, to 2029. Not an escape, a deferral, but it tells you the largest oncology drug on earth still has years of full pricing ahead of it. So near term, prices for drugs like this hold. And if the politics eventually do reach this one, remember the offset: the price drops, but the volume keeps rising into the same unmet need, so the revenue is cushioned, not erased. QUESTION #3 - HOW DOES THE MONEY BUILD? Now watch it build. Not one number but a curve, because that is how a drug like this actually arrives, and it is the honest answer to when. And read the clock the way we did in the Gulf: each door starts counting from the day it is approved, not from today. Year 1 is the first year after an approval that does not yet exist, and may never come at all. The two approvals will not land together, sepsis later than cancer, so read each curve from its own start, not the same calendar year. THE FIRST DOOR: CANCER Every year is the same simple sum: pool, times share, times price. The pool is the one we counted, up to 800,000 patients. The price is a net 120,000 dollars, the real after-rebate figure a payer actually hands over, not the 322,000 sticker that only ever gets billed. And the share is the one thing that moves, climbing year by year as the drug reaches more of the people who need it. So it is 800,000, times that year's share, times 120,000, from the day it is approved: - Year 1: 800,000 x 1.5% x 120,000 = about 1.4 billion dollars. - Year 3: 800,000 x 5.5% x 120,000 = about 5.3 billion. - Year 5: 800,000 x 10% x 120,000 = about 9.6 billion. - Year 10: 800,000 x 15% x 120,000 = about 14.4 billion, where the share meets what the budget will carry. Around year twelve, at its peak: about 15 billion, the last climb coming from the net price creeping up the way Keytruda's did, not from more patients. That is a real drug growing fast for a decade, and the speed is deliberately Keytruda's, because a survival drug gets adopted fast. But here the honesty matters, because it is the question people ask. Keytruda reached 30 billion in about ten years, and it did it by stacking around forty approved indications across some twenty cancers, not by one door climbing forever. This is one door. So it climbs Keytruda-fast to about 15 billion, and then, like every drug, it meets the wall: around year twelve or thirteen the patent lapses, cheaper copies arrive, the price erodes, the very cliff Keytruda itself now faces. One door rises, and one day it falls. The way you reach Keytruda's actual scale is the way Keytruda did, by opening the next doors one cancer at a time, and that is the next post. THE SECOND DOOR: SEPSIS Now the honest hard part, and we want to say it before a single number: sepsis is the most difficult thing in this whole post to size, because nothing like this drug has ever succeeded here. There is no ANKTIVA to point to, no adoption curve to borrow, no approved price to anchor. It is the graveyard where a generation of sepsis drugs has died. So read this entire door as the widest dial in the post, not a forecast. Start with the one thing we do know, the pool. About 850,000 Americans a year go septic and lymphopenic, a touch bigger than the cancer pool. In the Gulf this was the larger of the two doors, because that young region sees little cancer; in older America the cancer pool catches all the way up, so here the two are twins. By raw size, sepsis could be every bit as big as the cancer door. Here is the twist that makes it land beside the cancer door despite being the harder one to open. It is the slowest ramp in the post: it strikes in intensive care in hours, not over months of chemo; its trial is the furthest behind of all, so its approval and its clock start years after the cancer door; and payers are wary of a category that has failed them before. Slow to take up. But it is priced at half, about 60,000 for a short acute course instead of 120,000, and by the same budget logic that runs through this whole post, half the price lets twice as many patients fit under the same spending. Harder to adopt, but cheaper per patient and vast in number, it ends up right beside the cancer door. From the day sepsis is approved: - Year 1: 850,000 x 1% x 60,000 = about 0.5 billion dollars. - Year 5: 850,000 x 5% x 60,000 = about 2.5 billion. - Year 10: 850,000 x 10% x 60,000 = about 5 billion. - At its peak, roughly one in four reached, not because sepsis is adopted faster than cancer but because at half the price the same budget stretches over twice as many patients: 850,000 x 25% x 60,000 = about 13 billion. Which is the same size as the cancer door, exactly as it was in the Gulf. And it is still the widest dial in the post: no drug has ever proven sepsis can be cracked at all, so if you doubt it, turn this whole door down. Put both American doors at their peak, each a decade or more past its own approval, and the picture is this: roughly 28 billion dollars a year, from the collapse of the immune system alone, in one country. That would sit among the ten largest medicines on the planet by today's standards, and it counts not one of the other cancers still to come in the plan. WHO DOES IT TAKE THE MONEY FROM? The first question about a number this big is always who it takes the money from. The answer is almost nobody, because it replaces almost nothing. Chemotherapy and radiation are still used exactly as they are today; ANKTIVA is the layer that repairs the immune damage they cause, not a substitute for them. There is no lymphopenia drug to displace, and it does not fight the checkpoint drugs like Keytruda either; it works alongside them, rebuilding the very immune army those drugs need, and in its own trials it was added on top of a checkpoint inhibitor in patients who had stopped responding. So this is new spending, in a category that does not yet exist, the way immunotherapy grew the whole cancer market instead of carving up the old one. And that one fact, new money rather than borrowed money, cuts two ways at once, and both matter. It is why the prize takes from no one, and why the ceiling is so high. And it is the deepest reason that climb, fast as the demand for it is, still takes a decade to build rather than spiking overnight: the patients want it fast, but net-new spending is the hardest kind for a health system to absorb, so the money arrives phased, a few billion of fresh budget at a time, no matter how good the drug is. A drug that simply swaps in for another can be paid for at once, because the money is already in the system. This one has to be found, so it builds the way we drew it, a decade of steady climbing, not a spike. The one thing that could still bite is not chemo or Keytruda but a future immune-restoration rival splitting this new category, the way Opdivo split the checkpoint market with Keytruda. We assume ANKTIVA keeps it. Turn that dial down if you expect company. THE CEILING, NOT THE PLAN So what about the thirty-nine billion we opened with? It was never a lie. It is the same cancer door, at the same one-in-seven share, but priced at the full 322,000 sticker instead of the 120,000 a payer actually pays: 800,000 x 15% x 322,000 is about 39 billion. The naive number was never wrong about how many people. It was only wrong about the price. That is the ceiling of this one American door, cancer alone, in one country, every dial turned to its maximum at once, which no budget ever allows. Do not confuse it with the whole plan; that number, every cancer and every country, is still two posts away. The real path here is the climb below it, and it is one of the biggest drugs in the country for as long as it runs. So those are the three questions, and they point to one answer: a real, rising drug, climbing toward twenty-eight billion a year across both doors. But the math is the easy part. What is left is the reality around that number, and it cuts both ways: one reason it could climb faster than a launch from a standing start, and one reason America may be the very last place to feel it. THE RUNWAY IS ALREADY CLEARED Here is something almost nobody has noticed. In America, the FDA has already opened an expanded-access program for lymphopenia in solid-tumor patients, so the pathway exists before any approval does. Because it runs as expanded access the company cannot profit from it, so whatever demand shows up is real, not bought. And demand is showing up: the founder has said the requests climbed from about ten thousand when he first mentioned them to around thirteen thousand a couple of months later, and this is before a dollar of reimbursement exists. Hold that number against the pool, because it matters twice. Thirteen thousand requests is only about one to three percent of the patients this door could reach, so the demand is real but the room above it is enormous. When a real approval and a real price finally arrive for the cancer door, it does not start entirely cold. Part of the runway is already cleared, the kind of thing that can let a number climb faster than a launch from a standing start. BUT AMERICA IS LAST TO ITS OWN PRIZE Here is the sting. Everything above is real population and real math, and in America it is also the furthest away. The FDA has approved ANKTIVA for one narrow bladder-cancer indication and nothing else. For lymphopenia there is no approval and no dedicated trial of its own. The evidence lives inside the cancer trials, where ANKTIVA reverses the immune collapse and the recovery tracks with survival, and that, on top of ANKTIVA already being an approved drug, is what earned it the RMAT designation and the expanded-access program. But the randomized trial that would prove cause is enrolling in lung cancer, and it has not read out. That is real, but it is the start of a years-long road, not the end of one. Meanwhile ImmunityBio has said it is already in talks with Gulf regulators about widening ANKTIVA's approved cancer indications, while America waits its turn. Read that carefully, because it is not the story it looks like. Nobody is taking this drug from Americans and handing it to foreigners; Americans can already reach it through that program right now. It is a story about speed. The country holding the single biggest version of this prize has the slowest door to it, and the name on that door is the FDA, and the FDA does not hurry. NONE OF IT IS SIGNED Plainly: nothing is approved for lymphopenia or sepsis anywhere on earth, the United States included. Everything here is the size of a prize, not a promise that anyone collects it. And the clock on every one of those years starts at an approval that has not happened and may never: Year 1 is the first year after that day, not a year from now. The patient math is real and sourced. The price is a number we chose and labeled. The share of patients reached is a dial, and we have handed you the dial. The survival benefit is a real but unproven signal, not a settled fact. The receipts, every figure and its source, are in the reply below. None of this is advice. THE NUMBER YOU ASKED FOR So here is the American number you asked for. Not a single figure but a climb: a real, growing drug within a few years of approval, a blockbuster within a decade, peaking near 28 billion dollars a year across both doors, lymphopenia and sepsis, before the patent cliff pulls it back. From one country and two doors alone, that would rank among the ten largest medicines on earth by today's standards, and it is still only the modest opening of a far larger plan. And could the real number land far from this? Of course it could. This is a sizing, not a prophecy, and every input in it is a judgment that could prove too low or too high: how many patients, how fast they are reached, what a payer actually pays, and whether the survival benefit holds up at all. We built it as honestly as we know how and showed every step, because the point was never to hand you one number to trust. It was to hand you the dials. If you believe the drug is stronger than we assumed, turn them up; if you think we are dreaming, turn them down. The number moves with you. WHAT COMES NEXT So keep in mind what this is: one country, two doors, the careful corner of the whole three-year plan, with the two big bets named out loud. Two posts still to come, and each one changes the scale. Post three, up next, goes past these two immune doors to the rest of the plan: every other cancer in it, counted this time for the whole world at once, not one country at a time. And then post four, the finale, asks the wildest question of all, the one almost no one says out loud: whether a drug that rebuilds the immune system could break the ceiling on what a single company is allowed to become, an Nvidia of biotech. We kept every number below its ceiling today. Starting next time, we take our hands off them.

$IBRX On Friday, Patrick Soon-Shiong went on the Sean Spicer show and, in one quiet sentence, described the biggest opening this drug has ever had. The UAE, he said, wants to take ANKTIVA "to the next level, which is lymphopenia," for "all cancer types." Not one cancer. The failing immune system itself. If you follow this company, you felt what happened next. The boards lit up. Stocktwits, X, Reddit, everywhere we gather, one word started bouncing around: lymphopenia, this is going to be massive. They may well be right. But here is what struck us. In all that noise, we have not seen a single person actually stop and put a number on it. We seem to split into two camps. Those who are certain it is about to be enormous, and those who have never heard the word and quietly have no idea what it even means. Both are guessing, because nobody has done the arithmetic. So we did, the way we did it for Germany a few days ago, and for the Gulf before that. We took the sentence apart, counted the patients, put a price on it, and left every dial in your hands. Nothing is signed. This is not a prediction and not advice, just pure curiosity about a question the whole board is arguing over. What fell out of the math surprised us. Build it with us below. WHAT HE ACTUALLY SAID In his words, the UAE told him: "we want you to start here, because we want to then take you to the next level, which is lymphopenia." In their eyes, he said, the drug works "for all cancer types." He was careful, over and over, to say this is the UAE, not the FDA. But the direction was unmistakable. Bladder and lung were the start. Lymphopenia, treated with a simple injection under the skin in anyone whose immune cells have fallen too low, is where they want to go, and he says they already have the data. Separately, talking about the trials he is chasing, he named one more frontier: sepsis. WHY THE UAE, AND WHY IT GOES FURTHER THAN THE FDA To see why this is not idle talk, look at what the UAE has already done. Twice. For bladder cancer, the American FDA cleared ANKTIVA for one form of the disease. The UAE went a step further and added a second group the FDA still has not cleared, and will not even rule on until January. Further than the FDA. And further than Saudi Arabia, which on bladder matched the FDA exactly. For lung cancer, the FDA has cleared nothing at all. The Gulf approved it anyway, Saudi Arabia first and then the UAE, on the trial data alone. That is the pattern. The UAE does not wait for the FDA, and it does not stop where the FDA stops. Nothing here is approved yet, and it may never be. But if it does move on lymphopenia the way it moved on bladder and lung, the question becomes not just whether it approves, but how far past the FDA it would go. AMERICA ALREADY DREW THE FIRST LINE And here is what makes it concrete. There is a program in the United States right now that already lets doctors give ANKTIVA to cancer patients whose lymphocyte counts have collapsed. It is not a full approval, it does not endorse the benefit, and it earns the company almost nothing, because these programs are provided at cost. But it matters for a simpler reason. The American system has already accepted, in practice, that these are patients this drug is meant to reach. So the floor here is that group, cancer patients with wrecked immune systems, and the ceiling is the "all cancer types" the UAE described. Sepsis, the seriously ill beyond cancer, is a separate program we will size on its own. We sized both. THE SIZE OF YOUR ARMY Think of your immune system as a standing army, and your lymphocytes, chiefly the T cells and natural killer cells, as its soldiers. Lymphopenia is simply that army falling below fighting strength. And it is not only a cancer problem. The ranks fall in cancer patients on chemotherapy or radiation, and they fall just as hard in sepsis, when an infection overwhelms the body. When too many soldiers are gone, the body can no longer hold the line and infection walks straight in. Those two sick groups, cancer and sepsis, are the ones we will count, and nothing else. There is even a headcount. It is called the ALC, and it sits on almost every blood test ever run. A large study in a leading American journal found that as that headcount falls toward 1,000, all-cause risk of dying roughly doubles, and for specific causes like cancer, heart disease and infection the risk runs several times higher. It is an association, not proof that the thin ranks themselves do the damage. But the pattern is hard to miss: the smaller the army, the worse the odds. And that is the whole point of the drug. ANKTIVA's entire job is to call up reinforcements and rebuild the count. So the thesis fits in one line: the size of your immune army predicts your survival, and this drug rebuilds the army. NOW LET'S BUILD THE NUMBER So how big is the door, if it opens? Nobody can hand you one number, because it turns on the one thing nobody has defined yet: how wide the label is. So we will not hand you a number. We will build it in front of you, in four steps, and hand you every dial. Turn any one you like. STEP ONE: COUNT THE FALLEN Start with the cancer army, because that is the part we can actually count. - The Gulf sees about 42,500 new cancers a year - Of those patients, roughly 65 percent are put on chemotherapy or radiation, the treatments that thin the ranks - Of those, somewhere between half and two thirds watch their immune army fall below strength Multiply it through and you land at about 15,000 people a year, in the Gulf alone, whose defences this drug is built to rebuild. That is the grounded floor of the pool, and every number in it comes from published cancer data. STEP TWO: THE PRICE NOBODY WILL PRINT Now what a course costs, and this is the softest number in the whole post. There is no approved price for this use, because there is no approved course for it yet: PSS described an injection under the skin, and nobody has published a dose, a schedule, or a price. So we borrow one. In America, the approved bladder course runs about 322,000 dollars. Outside America, drugs like this sell for something like 40 to 70 percent of the US price, so we will use about 175,000 dollars as a stand-in. Too high, too low? Change it. The math does not care. STEP THREE: HOW MANY ACTUALLY GET IT No new drug reaches everyone at once. It reaches a sliver first, then grows as doctors and payers come on board. So turn that dial: 5 in 100, 15 in 100, 40 in 100. STEP FOUR: NOW MULTIPLY Put the three together, 15,000 people, about 175,000 dollars a course, and the share who actually get it: - 15,000 x 175,000 x 5 percent = about 130 million a year. - 15,000 x 175,000 x 15 percent = about 400 million. - 15,000 x 175,000 x 40 percent = about a billion. Now hold that against the company as it stands today: ImmunityBio sold about 113 million dollars of everything, in all of last year. So the middle of this, on cancer alone, in one region, is already several times the entire company. And cancer is only the first of the two sick groups this drug is built for. A SECOND PROGRAM, AND A BIGGER ONE Everything to here is the cancer conversation, the one the UAE described. But the same idea, rebuilding a collapsed immune army, applies to sepsis, and that is a separate program the company is already running, not part of the UAE lymphopenia talks. Its sepsis work has an early-stage protocol already submitted to the FDA and a Phase 3 planned across Saudi Arabia, the United States and the UAE. It is earlier and less certain than the cancer work: where cancer has real survival data behind it, sepsis has only an early trial and a promising idea so far. But the pool is far larger. In the Gulf, the number of sepsis patients whose immune army falls is not 15,000. It is on the order of 90,000 a year, and that count is a rough estimate. It is the same drug, at the same price per dose. The difference is that sepsis is an emergency, not a years-long course, so a patient gets a short burst rather than the full cancer regimen, call it about 60,000 dollars a head. - 90,000 x 60,000 x 5 percent = about 270 million a year. - 90,000 x 60,000 x 15 percent = about 810 million. - 90,000 x 60,000 x 40 percent = about 2.2 billion. So the second door, if it opens, is bigger than the first. Keep them apart in your head, because they are apart in reality. At a realistic uptake, cancer lymphopenia, the one the UAE is discussing now, is worth roughly 400 million to a billion a year; and sepsis, still a planned trial, roughly 800 million to over two billion. Two separate doors, the same drug, one region. Neither is signed. AND THIS IS ON TOP OF EVERYTHING ELSE Hold on to one thing: none of this replaces what the drug already has. It adds to it. What ANKTIVA is already cleared to sell, in America today, in Europe for bladder, and in the Gulf for bladder and lung, is a real, approved business worth a few hundred million dollars a year as it ramps. Everything we just built, for lymphopenia and for sepsis, sits entirely on top of that. If these doors open, they do not add another engine. They dwarf the ones already running. The full tally is at the end. WHERE THE MONEY REALLY SITS Whichever door you are looking at, the money does not arrive as one lump, and where it sits is not what you would guess. Take the cancer middle case, about 400 million dollars a year. More than half of it, call it 220 to 260 million, is the Gulf state buying this for its own citizens, the same governments already spending well over a billion a year flying their patients abroad for care they could soon give at home. Another hundred million or so runs through the private and employer insurers that cover the expatriate majority, where cancer coverage is real but uneven. The rest, a few tens of millions, is patients sponsored in from neighbouring countries and a small tail of the wealthy who travel for what they cannot get at home. The sepsis program, if it lands, flows through the very same channels. Nothing here leans on Dubai's wellness tourism, where cancer barely registers. The full split, region by region and door by door, is in the branded table attached to this post. WHY A GOVERNMENT WOULD WRITE THAT CHECK You might reasonably ask why any government would spend this kind of money. PSS never quite spells it out. But put on a detective's hat and it takes about a minute, because he left both clues lying on the same show. Clue one: asked about the economics of people living longer, he reached for a paper in Nature Aging that puts a dollar figure on healthy years of life. Add a single year to average life expectancy, it found, and in a country the size of the United States the value runs into the tens of trillions of dollars, through a healthier, more productive population. Clue two, a few minutes earlier: he was describing the Gulf, and he made a point of their population being young, average age around thirty, and of how keeping it healthy and productive for the decades ahead is exactly what they are spending their sovereign wealth on. Lay the two side by side, and the answer is obvious. To a young, rich country doing that math, a drug that rebuilds the immune system is not a line on a health budget. It is an investment in its workforce. In its future. In the long survival of a small nation betting everything on its own people. That is why the biggest cheque here is a state cheque. THE VERSION WE THREW OUT That same logic points at a much bigger version, and it is worth being honest about why we still left it out of the numbers. Imagine treating people who are not sick at all, healthy and feeling fine, just carrying a slightly low count, on the theory that rebuilding their immune system buys them healthy years. Do that across a young, wealthy population and you can conjure single-digit billions in the Gulf, tens of billions once you add America. This is the longevity frontier PSS keeps pointing at, and the economic case for it is real. But it is a thesis, not a market. No health system reimburses an expensive injection for people who feel well today, and the proof that it extends their lives does not yet exist. So we keep it out of the cash math, as the prize beyond the prize, not a number anyone collects yet. Every figure above is sick patients, real reimbursement, real data. THE WHOLE BOARD It is easy to lose the numbers along the way, so here is the whole board laid out plainly. Only one of these is actually in the bank yet: America, where ANKTIVA is running near a 200 million dollar annual pace. Two more doors are open but barely earning, Europe, which we sized at around 120 million a year, and the Gulf's bladder and lung approvals, sized between 140 and 300 million. Approved and real, but the money has only just started to flow. And the two doors we just built, both still unsigned, both in the Gulf alone: cancer lymphopenia, the one the UAE is discussing now, worth roughly 400 million to a billion dollars a year; and sepsis, a separate planned program, worth roughly 800 million to over 2 billion. Neither indication exists yet. Yet either one, at a realistic uptake, already beats everything the drug sells on the whole planet today. And even this is not the whole board. Back in February, ImmunityBio laid out a formal three-year plan: more than a dozen cancers and over twenty trials, from pancreatic and colorectal to brain, breast and lymphoma, plus a bigger bladder filing already headed to the FDA. Most are earlier and less certain than what we sized here. But we put numbers on only a corner of that plan. Every other door is upside, and not one of them is in a single figure above. And none of it counts the developing world, the millions who could never pay for this themselves but whom a global health fund could pay to reach, which is exactly why ImmunityBio just made the former head of the World Bank its vice chairman for global access. NONE OF IT IS SIGNED One line matters more than every number above it: none of this is signed. The UAE has not approved anything for lymphopenia. PSS says he is in conversations and has the data. Conversations are not a purchase order. Everything here is the size of the prize, not a promise that anyone collects it. Every figure is a dial you can turn, and we picked what we could defend and showed our work. The receipts, every number and its source, are in the reply below. So here is the whole thing in one line. There is a number on your blood test that quietly predicts how long you live. There is a drug that can move it. And there is a government that keeps approving what the FDA will not. Put those three together and the prize, across two doors in one small region, runs from a few hundred million to many times over this entire company, before America is even in the room. None of it is signed. All of it is now on the table. And you are no longer in the dark about how big the table is.

And remember, everything above is the Gulf alone. The US is a different order of magnitude: the biggest market on earth, at the highest price, where these same two doors, lymphopenia and sepsis, are worth multiples of the numbers above. That is the breakdown I could do next. Want the US numbers? Say the word.

On Wednesday, @DrPatrick posted something that could one day rival the entire business ImmunityBio has built so far. It looks like paperwork: a finished factory run of labeled vials. Zoom in. The writing on those vials is German. It is a boxed, shippable medicine, which means a German patient whose bladder cancer had run out of options can now actually receive it. This week, approved on paper became a real product on a real shelf. Here is how Europe got here, and exactly what it is worth. Every patient number is real and sourced. The one number I invent, the price, I label as invented and hand you the formula to run it yourself. HOW EUROPE GOT HERE An engine does not arrive whole. It is built part by part, in order, and it stays silent until the last piece drops in. Piece by piece, while the market kept its eyes on the United States, ImmunityBio machined the parts of a European engine. Here they are, in the order they were made: - February 2026: the European Commission granted ANKTIVA a conditional marketing authorization. Not one country. Thirty. All twenty-seven European Union members, plus Iceland, Liechtenstein and Norway, in a single approval. - The same window: ImmunityBio opened an Irish subsidiary in Dublin, ImmunityBio Ireland Limited, to hold that authorization and run the European business. - And it signed Accord Healthcare to commercialize the drug across roughly thirty countries, with an eighty-five-person sales force already in place. - August 2026: the first German label-and-pack run is done. His words: "Global access continues. Unstoppable." Why Germany first? Two reasons. It is the largest pharmaceutical market in Europe. And under Germany's pricing law, a manufacturer sets its own price freely for roughly the first six months before any negotiation begins. The first European market you launch is the one that turns into revenue the fastest, at a price you choose. Approval, then a company to hold it, then a sales force to sell it, then a product to ship. Every part is now in place. Germany is where the engine turns over for the first time. NOW CRUNCH THE NUMBERS. GERMANY FIRST. The European approval is narrow and specific: BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. That is the exact door, and for now ANKTIVA is the only drug Europe has approved to walk through it. The alternative offered to these patients is surgery, removing the bladder. Let us size it the same way we sized the world in earlier posts. Real epidemiology, one honest funnel, no hand-waving. Start with every bladder cancer in Germany: about 30,000 a year. That is grounded. The German cancer registry and the global GLOBOCAN database bracket it. Now walk the funnel: - About 75 percent are non-muscle-invasive. 30,000 becomes about 22,500 - About 20 percent of those are high risk. 22,500 becomes about 4,500 - About 35 percent of high-risk patients treated with BCG stop responding to it. 4,500 becomes about 1,575 - About 45 percent of those carry the carcinoma-in-situ pattern the European label covers. 1,575 becomes about 700 So the German pool ANKTIVA is approved to treat is roughly 700 patients a year. Call the honest range 400 to 1,500, because every step after the first compounds a soft fraction. Sanity check, because a number you cannot check is worth nothing. The same funnel gives the United States about 2,000 of these patients a year. Germany at 700 against the US at 2,000 is more than population alone would predict, and that is correct: Germans get bladder cancer noticeably more often than Americans, an older population with more smoking history. The two numbers reconcile. The German figure is not an artifact. THE ONE NUMBER I INVENT I do not know what ImmunityBio will charge in Germany. Nobody outside the company does. So I will invent a price, tell you it is invented, and show my reasoning. In the United States, a year of ANKTIVA runs around 300,000 dollars. European cancer drugs typically sell for well under half of American prices. So I will use 130,000 dollars a year for Germany. It is a placeholder. If you think it is wrong, change it. The formula does not care. WHAT THAT IS WORTH Now, no new drug reaches every eligible patient. Doctors adopt a new therapy gradually, and for some of these patients the standard alternative, removing the bladder, is chosen instead. So the honest move is not to guess one share, it is to show the revenue at several and let you pick. 700 patients, 130,000 dollars each, times the share who actually get it: - At 10 percent of them reached, about 9 million dollars a year - At 25 percent, about 23 million - At 50 percent, about 46 million And one thing about a first launch. BCG-unresponsive patients do not disappear. They live for years under surveillance, putting off having their bladder removed. So when a drug finally arrives, it does not only catch this year's new patients. It catches the pile that has been waiting. That backlog can make the first year or two considerably larger, a one-time bulge, before it settles to the steady number. Put 46 million against ImmunityBio's entire product revenue last year, about 113 million dollars. Germany alone, at a healthy share of patients, is worth roughly 40 percent of everything the company sold worldwide in 2025. From one country. For one narrow slice of one cancer. NOW THE WHOLE CONTINENT Germany is not the market. Germany is the doorway. It is about a fifth of Europe's population, and one of roughly thirty countries Accord is now built to sell into. Run the same funnel across the whole European Union and the eligible pool is not 700. It is somewhere around 3,500 to 4,000 patients a year. Take the middle, about 3,700. Reach a quarter of them, and that is roughly 900 patients actually on the drug. At the same invented 130,000 dollars each: 900 times 130,000 is roughly 120 million dollars a year. Sit with that. Roughly 120 million dollars a year, from a single narrow bladder-cancer indication across Europe. That is on the order of what ImmunityBio sold worldwide in all of 2025. A second engine, close to the size of the whole company as it stood a year ago. AND WE HAVE SEEN THIS NUMBER BEFORE Here is the part that should stop you. This is not the first time we have run this exercise and landed near the size of the whole company. In July, when the UAE approved ANKTIVA, we sized the other new market the same way. Saudi Arabia and the UAE, where the drug is cleared not only for bladder cancer but for late-line lung cancer that nothing else has touched. Different patients. Different door. A different price, because the Gulf is not Europe. And it came out in the same range: roughly 140 million dollars a year at a cautious count, and toward 300 million at the top of its range. One honest note, so you weigh it correctly. The European number rests on a large, insured, domestic patient pool. The Gulf number is softer: a smaller local population, topped up by patients who fly in from neighboring countries for a drug they cannot get at home. It is the more speculative of the two. But even its firm, government-paid floor is a nine-figure opportunity on its own. TWO NEW ENGINES, AT ONCE So count them. In all of 2025, ImmunityBio sold about 113 million dollars of ANKTIVA, almost entirely in America. Now add Europe, a second engine near that size. Then the Middle East, which we sized in July at roughly 140 million dollars a year, a third. Two whole new regions, each a nine-figure opportunity, both opening at the same time. Set them against that 2025 number and they come to roughly two of it at a cautious count, closer to three if the Gulf climbs its ladder. And the base is not standing still while the new engines start. America sold more than 50 million dollars last quarter alone, close to double a year earlier. These two regions stack on top of a first engine that is itself still accelerating. Same drug. More doors. And it is still not the whole map. It is not first-line bladder, the larger pool the company is testing now. It is not the United States papillary decision due January 6. It is not the developing world a global fund could pay to reach, the reason ImmunityBio just hired the former head of the World Bank. It is not sepsis, or the rest of the pipeline. It is two regions, sized honestly, against one. RUN YOUR OWN I am forecasting nothing. None of this is signed, none of it is guaranteed, and none of it is advice. The patient math is real and sourced. The price is a number I chose and labeled. The share of patients reached is a dial, and I handed you the dial. If you think 130,000 dollars is too high, cut it. If you think a European launch reaches more or fewer than a quarter of patients over time, move it. A first launch often starts nearer one in ten, which would halve these numbers and stretch them over more years. The engines are the same size; they just take time to reach full speed. The funnel is printed above, step by step. The receipts are in the reply below. Check any of them. THE CATCH The European approval is conditional. It rests on evidence the company still owes regulators, and a conditional approval can be narrowed. The price is unknown, and Europe pushes prices down, not up. Penetration in a brand-new market is never fast and never certain. And ImmunityBio has told its own investors it needs to raise money to keep going, which means the shareholders who own this today may own a smaller share of it by the time these engines are collected. None of the numbers above are promises. They are the size of the opportunity, not a schedule for collecting it. But the opportunity is real, and it is finally physical. For two years this was a map. Approvals, subsidiaries, partnerships, plans. On Wednesday it became a boxed vial with a German label, sitting on a line, ready to ship. The map just became a truck. And the truck is only leaving the first city.

$IBRX How does a drug company get RICHER by selling its medicine for one percent of the price, or giving it away outright? It sounds impossible. It is one of the most powerful moves in modern medicine, three companies have already proved it with hard cash, and it is exactly what ImmunityBio just set up by hiring Jim Kim. Someone asked the question everyone else was too polite to ask. Here is the answer, in receipts and in math, and a formula so you can run your own. CHANGE WHO PAYS Kim's job is not to make ImmunityBio sell cheap and eat the loss. It is to change WHO PAYS. A poor patient cannot buy the drug at any price. So you find a third party with deep pockets and a mission, a global fund, a foundation, a sovereign, the World Bank, and get them to sign an order to buy it in bulk for those patients. The patient pays nothing. The funder pays. The company gets a check it never had. The price per dose drops. Watch what happens to the check. THE WORLD HAS DONE THIS THREE TIMES HIV. When the world decided to treat HIV in poor countries, it did not bill patients, it built funds. The US program PEPFAR alone has spent over $110 billion since 2003 and is credited with saving 26 million lives. The cost of a year of treatment fell from $1,200 to $58. Now multiply $58 by tens of millions of people, every year, paid by a government. One of the largest drug-buying operations in history, built on low price times colossal, funded volume. Vaccines. In 2007 the Gates Foundation and five governments put $1.5 billion into a fund to buy pneumonia vaccines for the poorest children. Who collected it? Pfizer and GSK, the on-patent makers, exactly like ImmunityBio with ANKTIVA. Doctors Without Borders campaigned for years to stop it, on the grounds that Pfizer and GSK made too MUCH money. Read that twice. The complaint about funded procurement is that the drug company profits handsomely. That is the opposite of a giveaway. Hepatitis C. Gilead's pill costs $84,000 a course in America. In Egypt, Gilead sold the identical drug for about $300, less than one percent of the US price. Same drug, same year, two buyers, two prices. The $300 never touched the $84,000. Gilead booked over $10 billion from the drug in a single year, almost all of it from that $84,000 US price. The cheap channel did not create the fortune. It added poor-world volume on top of one the rich market already paid for. WHY IT IS PURE UPSIDE FOR IBRX It does not touch the rich markets. The US, the Gulf and Europe keep paying full price. The funded channel is added underneath, poor-world volume that was otherwise zero. The company keeps the volume: ANKTIVA is on patent and ImmunityBio makes it, so it fills the funded orders itself, it is Pfizer in the pneumonia story, not a bystander. And its whole design, off-the-shelf, AI robot-made cells at a fraction of today's cost, is built for low price and huge volume. It IS the model. AND WHAT DOES THE PAYER GET? Fair pushback: none of this works unless someone actually writes the check, so why would they? Because a funder is not a charity being asked a favor. Each kind gets something it already wants. A government gets the most powerful sentence in diplomacy. "We cured your children's cancer" buys loyalty no treaty can, which is why America's PEPFAR and the Gulf states already pour billions into health across the developing world. A country that depends on you to treat its sick does not easily become your enemy. And in today's climate that is worth more than ever. For twenty years China has bought the developing world with roads, ports, and loans; the West and the Gulf answer with health. A cure is the one bid no rival can outspend, out-loan, or sanction, and no nation forgets who showed up while its children were dying. A foundation gets its mission. Gavi, the Global Fund, the Gates Foundation exist for precisely this. Buying medicine in bulk for people who cannot pay is not a detour for them. It is the entire job. A development bank gets a return. Cancer kills working-age adults, and healthy populations grow economies. That is not sentiment, it is the World Bank's actual doctrine, health as an investment that pays back, and it is the doctrine Jim Kim spent seven years running. THE MAN WHO FITS EVERY ROOM That is the whole reason Kim is the hire. He does not represent one payer. He has BEEN each of them: the man who scaled treatment for a global health program, who ran the development bank, who now sits inside the largest pool of capital on earth. He can walk into any of those rooms and make that room's own argument back to it. That is what ImmunityBio just bought. @DrPatrick is not hiding where this goes. On July 28, the night the UAE's broadest-yet approval hit the wires, he posted three words: "Global expansion unstoppable." Hiring Kim is how you make an unstoppable thing actually pay. So the demand side is real. Now the size of it. CRUNCH THE NUMBERS The formula is one line: patients a funder covers X price per course = revenue Two dials. I will hold a deeply discounted $5,000 a course, a fraction of the roughly $300,000 ANKTIVA costs in the US, and keep every patient count to a small FRACTION of its pool, because a funder never covers everyone. Then I walk straight up ImmunityBio's own pipeline, one real program at a time, and stack them. For scale, the company's entire drug revenue today runs about $200 million a year (an annualized run-rate; full-year 2025 was $113 million). The funder story is not the one approved indication, last-line lung, which is a rich-world use the Gulf already pays for. It is the pipeline, aimed first line at the poor world's biggest cancers. Every disease below is a real ImmunityBio trial, none of them approved for these uses yet. And one limit up front: each pool is the whole disease's yearly cases, while today's trial targets a narrower slice, so the small fractions I cover stand in for both, and the full pools only open as the first-line programs read out. Now stack them. - CERVICAL and other HPV cancers (Phase 2 vaccine). About 660,000 cervical cases a year, nine in ten in poor countries, which makes it perhaps the single most fundable cancer on earth. Cover 200,000 at $5,000 = $1 billion. - PANCREATIC cancer (Phase 2, granted the FDA's RMAT accelerated status). One of the deadliest there is, about 510,000 new cases a year. Cover 100,000 = $500 million. - NON-HODGKIN LYMPHOMA (Phase 1 CAR-NK). About 550,000 new cases a year. Cover 100,000 = $500 million. - GLIOBLASTOMA, recurrent brain cancer (Phase 2/3 registration trial). Cover 30,000 = $150 million. - BLADDER, first line (Phase 2B, 85% enrolled), about 45,000 a year. Cover 20,000 = $100 million. Five real programs, none approved yet, and already past $2 billion a year on a drug sold at a charity price, more than ten times the whole company. And that is before the biggest number of all. THE CEILING - ALL CANCERS, FIRST LINE. The whole thesis in one line, and an unproven one: one immune-restoration layer, given early, across cancer. About 20 million new cancer cases a year worldwide, the majority in countries that cannot self-fund. Cover a tenth of the poor-world pool, roughly 1.5 million, at $5,000 = $7.5 billion a year. And that is still only cancer. ANKTIVA is also in a Phase 2 sepsis trial and holds US clearance for lymphopenia, pools bigger again by an order of magnitude. I am leaving those two blank on purpose, and here is the reason: the sepsis trial has no results yet, and lymphopenia is too broad to size without guessing. So I will not pretend to. Just know that if either one lands, it does not add to the stack above. It makes the whole stack look tiny. And every dollar of all of this stacks on top of the rich-world business, where the same drug sells for the full $300,000 a course, sixty times what a funder pays. The poor world is the second engine, sitting on top of the first. RUN YOUR OWN Every patient count above is a fraction I made up, and the price is a number I made up. None of these are approved for the poor world today; every rung is a real ImmunityBio trial, not a promise that it lands. I am forecasting nothing, and none of it is signed, and none of it is advice If you think the price is higher, or lower - a global fund negotiates hard, though a cell therapy will never be as cheap as a pill - or the covered share wider, or the trials sooner, change the inputs and run it yourself. The formula never moves: patients x price = revenue. I am only showing you the shape, and the shape is already many times the company before the biggest number, and then it climbs off the page. And every hard number here - every disease count, every dollar, every one of those other companies - is real and sourced. The receipts are in the reply below. Check any of them. THE CATCH None of this is on the books. It is the opportunity Kim's hiring creates, not revenue today. An appointment is not a purchase order. But the man whose entire career is turning "someone should pay for this" into "here is the order" now works there. So no. They did not hire a man to give the drug away. They hired the one man alive who can make the whole world pay for it. Free for the patient. A bargain for the payer. Enormous for the maker. Those three were never in conflict. That was the plan all along.

$IBRX ImmunityBio's second-quarter numbers are out, and which company you think you are looking at depends entirely on where you look. The company's own announcement leads with the good news, and it is genuinely good: record sales, up ninety-two percent, the best quarter in its history. Scroll down into the financial tables, though, and the picture gets heavier, a two hundred and thirty million dollar loss for the quarter, a formal warning about the company's ability to keep going, and a stack of obligations most readers never see. Both of those are true at the same time. This is the whole thing, in plain English, for people who do not read balance sheets. The company led with its good news, so we will do the opposite and start with the number it left in the fine print, the scary one, because that is the one that trips people up. We will clear up what it actually is, then walk the rest, the genuinely good and the genuinely worrying, side by side and in the company's own words. By the end you will understand this company better than most people who own it. And every fact in here has a receipt. Every number and every quote comes straight from the company's own filings with the Securities and Exchange Commission. The full source list, the exact document and the exact line for each claim, with the filing's own words quoted, is in the comment below. Check any of it. THE SCARY NUMBER Net loss for the quarter: 230 million dollars. The same quarter a year earlier, the second quarter of 2025, lost 93 million. So the loss got bigger, about two and a half times bigger, in a year when everything was supposed to be improving. On the surface, that looks like a company bleeding out faster. Hold that thought. Most of that number, though not every dollar, is about to come apart in your hands. WHERE 141 MILLION OF THAT LOSS IS ON PAPER, NOT CASH Here is the single most important thing to understand about this company's accounting, and almost nobody explains it simply. Years ago the founder, Patrick Soon-Shiong, put his own money into the company as a special kind of loan, one that turns into shares instead of being paid back in cash. Accounting rules say you have to re-measure what that loan is worth every quarter and record the change as a profit or a loss on paper. When the company becomes more valuable, that loan-that-becomes-shares becomes more valuable too, and the rules force the company to record the increase as a loss. Read that again. The company was punished, on paper, for being worth more. The same trick happens with a stack of warrants, which are simply rights to buy shares at a fixed price, and which also gain value when the company does. SO WHAT IS THE REAL LOSS Add those paper marks together and they came to 141 million dollars this quarter, most of it the founder's convertible loan and the rest those warrants. Not a penny of it was spent. No money left the building. Nobody wrote a cheque. It is ink, not cash. Strip it out and the real, cash-based loss was 81 million dollars, and that number actually shrank from 90 million in the second quarter of 2025. So the honest translation of that 230 million dollar loss: the part that grew is the part that is not cash, and the part that is real got smaller. To be precise, that paper mark is not nothing, it is the accounting shadow of shares the company will hand over later, and we will come back to that cost with both eyes open. But no cash moved this quarter. NOW THE NUMBER THAT ACTUALLY MATTERS In three months, ImmunityBio sold 50.7 million dollars of its cancer drug ANKTIVA. A year ago that number was 26.4 million. It nearly doubled. Up 92 percent. This was not a fluke quarter. It is the eighth quarter in a row that sales grew over the one before. In the first quarter of this year it was 44 million. Now 50.7. Every three months, for two straight years, more. Add the first half of this year together and it is 94.8 million dollars. The entire previous full year was 113 million. They did five-sixths of a whole year in six months. IS THE GROWTH REAL, OR BOUGHT And this is real demand, not a discount fire-sale. When sales jump this fast, the fair worry is that the company bought the growth by quietly slashing its price. This one did not. After every rebate and discount the system carves out, it still keeps about 83 cents of every gross dollar, barely changed from the quarter before. On a price that Medicare largely sets, that means the extra dollars came from more vials going into more patients, not from cutting the price to push product out the door. The growth is the real kind. WHY THIS DRUG IS AN ALMOST PERFECT BUSINESS Here is a number that will surprise you. To make and deliver that 50.7 million dollars of medicine, the company spent 298 thousand dollars. Not million. Thousand. That means for every 100 dollars of ANKTIVA sold, it costs them well under one dollar to produce. Around 99 cents on every dollar is left over. One honest asterisk: the cost is this low partly because the early batches of the drug were made and written off before approval, so the true ongoing cost to produce each new vial will run higher than a third of a cent. The margin is genuinely excellent and will stay excellent, just not literally ninety-nine percent forever. Once the sales cover the running costs of the company, nearly every new dollar of sales falls close to straight to the bottom line. That is the engine underneath everything else here. WHERE DOES THE MONEY ACTUALLY COME FROM Important, because it is easy to imagine sales pouring in from the new approvals you have been reading about. They are not. Not yet. Essentially all of this revenue is from one country, the United States, from one use, bladder cancer, delivered by American urologists and paid through Medicare under its own billing code, J9028. Saudi Arabia only launched this spring, and the United Arab Emirates was not approved until the very end of July, after this quarter had already closed. So the Gulf is a zero in these numbers, both countries, not a trickle. This is a one-country story so far. Sit with what that means, in both directions. The risk is real: this is one drug, one disease, one country, sold through so few hands that just four customers account for about ninety percent of it. That is genuine concentration, and it deserves respect. The other side is just as real: the company nearly doubled its sales, in its eighth straight quarter of growth, on that narrow a base alone. WHAT ABOUT THE GULF, AND ALL THE REST Everything else you have heard about, the Gulf, lung cancer, first-line, the FDA decision due in January 2027, is not in a single figure on this page. But be clear-eyed about what that upside actually is. An approval is not a sale. A drug can be cleared by a regulator and still sell slowly, and every one of these markets starts at zero and ramps over time, not overnight. But do not mistake slow for small. When we ran the Gulf numbers on their own, that market alone, once it is genuinely selling, could in time come to rival the company's entire current revenue, and on the more bullish math, more than double it. It is not a rounding error. It is a slow build from a standing start, still unproven, and worth exactly nothing in tonight's figures. Opportunity, not revenue, until it isn't. IS THE COMPANY RUNNING OUT OF MONEY The fair question, asked plainly, and here we will use the company's own words, not ours. The company holds about 357 million dollars in cash and investments. At the end of March it held 381 million. So the cushion shrank by roughly 24 million in the quarter. The truest measure of burn is the cash that actually left the building to run the business. This quarter that was about 66 million dollars, and it is shrinking, down from 75 million in the first quarter, because the sales are catching up to the costs. Against 357 million, that is roughly five quarters of fuel with no help at all, into 2027. THE SENTENCE THE COMPANY PRINTS ABOUT ITSELF Now the hardest sentence in the whole filing, because the company prints it about itself: there is "substantial doubt" about its "ability to continue as a going concern without additional funding or financial support." That is a real, legally weighted phrase, and any honest read has to say it out loud. In the very next breath the company says why it believes it will be fine anyway: its cash, its growing product sales, more share sales, and its ability to borrow from the founder's own entities should carry it past the next year. Both halves are true, and you deserve both. And the fuller scoreboard is heavier than one quarter: the loss for the entire first half was 863 million dollars, and across its whole life the company has lost 4.6 billion. So say it straight. This is not a company that is safe. It is a company whose business is finally working while it still depends on outside money to reach the finish line. So how does it keep the lights on while it closes that gap? This is the part that costs shareholders something real, and we are not going to hide it. THE REAL PRICE: THEY PRINT SHARES To cover the gap between what it spends and what it earns, the company raised, on a net basis, about 268 million dollars in the first half of the year. It came mainly from three places, and the details matter. - About 147 million was selling brand-new shares straight into the market. - About 54 million was warrant holders paying to turn old rights into new shares. - And about 75 million was a financing deal that trades a slice of future sales for cash up front. Notice who is absent from that list: the founder put in no new cash at all this year. He did the opposite. He converted 25 million dollars of his own loan into shares, shrinking what the company owes rather than adding to it. WHAT IT DOES TO YOUR SLICE Selling new shares has a cost, and it is not the drug's cost, it is yours. Picture the company as a pizza. Your slice is your ownership. Every time they cut new slices to sell for cash, your slice gets thinner. At the end of 2024 there were about 853 million slices. Today there are about 1.06 billion. That is roughly 207 million new slices, a quarter more, in nineteen months. Named plainly, that is the real bear case, and it deserves respect. NOW WATCH THE PACE Now here is a number almost nobody is talking about, and it may be the most encouraging one in the whole report, as long as we tell it honestly. Watch the pace, quarter by quarter. In the second and third quarters of last year the company printed 62 million, then 69 million new shares. This past quarter it printed under 6 million. The pace slowed sharply. But do not oversell it: in July alone, after the quarter closed, holders of old warrants exercised another six and a half million, more in that one month than in the whole prior quarter. That was a one-time cash-in of a specific batch of warrants, which cleared that batch, not the everyday share-printing. Still, it is a fair reminder that slowing is not stopping. Why does the pace fall? Because the reason to print is shrinking. A year ago the gap between what the company earned and what it spent was enormous, so it sold shares by the tens of millions to fill it. Today, with sales nearly doubled and the running costs rising far more slowly, up about fifteen percent while revenue grew ninety-two, that gap is a fraction of what it was, so the printing shrinks with it. The dilution was never meant to be permanent. It is a bridge, though the far bank is not reached yet. WHAT IS STILL LOADED IN THE PRINTER Now be honest about the caveats, because they are real and they are large. Last quarter was especially light partly because the company had raised heavily the quarter before and was living off that cushion, and even so it still spent more than it took in. And the printer is nowhere near empty. It can still sell about 349 million dollars of new shares whenever it likes. Roughly 41 million warrants are still live on top of that. And the founder's loan converts into another 88 million shares if he chooses. The pace slowed hard this quarter, but the capacity to dilute a great deal more is fully loaded. What matters is the direction, and the direction so far is fewer new shares each quarter as sales climb, not more. Here is the honest question underneath all of it. This dilution is the genuine bear case, and it is not temporary by decree, only by arithmetic: the printing can slow toward zero only if and when sales grow past the running costs. That the business works is clear. What is unproven is whether they cross that line before they have thinned the pizza too far, and before the borrowed money behind it has to be dealt with. That is the whole game. WHAT THE BILLION DOLLAR HOLE ACTUALLY IS One more scary line, so no one can ambush you with it. On paper the company shows a one billion dollar negative net worth, and total obligations of 1.67 billion dollars. That sounds like a company drowning in debt. It is not a stack of ordinary bank loans, but it is not harmless either, and the honest version has teeth. Of that 1.67 billion, the larger piece is the founder's loan, held through his investment vehicle Nant Capital, now marked at 774 million. Its actual principal is about 480 million, it is designed to convert into shares rather than be repaid in cash, and the founder has been actively converting it, which shrinks it. That much is genuinely friendly. But it is not free: it charges real cash interest, roughly 14 million dollars every quarter, it comes due at the end of 2027, and the company itself says there is no assurance it can convert or refinance it. So even the friendly piece has a coupon and a deadline. MEET OBERLAND, THE SENIOR CREDITOR The second piece is the one the cheerful version leaves out. The financing deal, with a firm called Oberland under what is known as a revenue-interest agreement, is not a well-wisher betting on the future. It is a senior, secured creditor. It ranks ahead of shareholders, and it is owed back nearly twice what it put in. On certain triggers, including the loss of a key approval, it can force the company to buy the debt back on demand, and if the company cannot pay, Oberland can move to foreclose on substantially all of its assets. The founder's note actually sits behind Oberland in line. So the true shape of the "hole" is this: a subordinated founder loan with a cash coupon and a hard 2027 maturity, standing behind a senior secured financier that can foreclose. Not a bank run waiting to happen, but a real set of claims that deserve to be seen. AND THE LAWSUIT IN THE FOOTNOTES And one more the company discloses that we will not bury, since we promised every scary number. It faces an arbitration claim brought by SRS, the representative for the former shareholders of Altor Biosciences, a company ImmunityBio absorbed years ago, seeking more than 200 million dollars, and it may separately owe up to another 164 million in cash on an earn-out if certain sales targets are hit. Neither is settled, both are contingencies, and the company says it may have to raise money to cover them. On a business already leaning on outside funding, that is a real line, not a footnote. THE TRAJECTORY, IN ONE PIECE OF MATH Forget every headline number for a second and watch one thing move. In the second quarter of 2025 the company's actual operating loss, the pure cost of running the business against its income, was 71 million dollars. This quarter, the second of 2026, with sales nearly doubled, it was about 62 million. The loss got smaller while the business got bigger. HOW FAR TO THE FINISH LINE That is the shape of the whole thesis. Revenue is climbing steeply. The cost of running the place is climbing too, up about fifteen percent over the year, but far more slowly than sales. The two lines are closing. The company's own chief executive has said he expects them to cross in 2027, on the strength of the bladder business alone, though he stressed that date is not fully pinned down, and he has quietly stopped repeating it since. And be honest about the size of the gap that is left: running costs this quarter were more than double the revenue, so sales still have to roughly double again to reach the crossover. It is a real trajectory in the right direction. It is not a short walk. WHERE IT STANDS TONIGHT So here is where ImmunityBio actually stands tonight. It sold more medicine than in any quarter of its history, keeping almost every cent of it. Its real losses are shrinking even as it grows. It is paying for the last stretch of the climb by thinning its own shares and leaning on borrowed money, which is the real cost and the real risk. Two more shadows belong in an honest picture: the pace of sales growth, while still fast, has been easing quarter to quarter, and a rival drug from Johnson and Johnson, called TAR-200, that spares patients the same failed therapy, has now been approved into the very same market. The thesis rests on that growth holding. And the doors to the future, the markets outside America just cracking open and the run of new approvals still ahead, from January 2027's FDA decision on a second bladder use to first-line and lung, have not opened yet and are worth nothing in tonight's numbers. THE TWO HALVES SIDE BY SIDE So set the two halves down side by side. - On one, a company doing five-sixths of last year's sales in half the time, at a margin most businesses only dream of, its losses shrinking as it grows. - On the other, in the same filing, the honest weight: it still burns cash, still leans on selling shares and on a senior lender that could foreclose, still says in its own words there is doubt it can stand alone yet, and still sells to four customers in one country. Both are true at once. Read only the cheerful headline the company led with and you would miss the weight underneath. Read only the loss buried in the tables and you would flinch and walk past a real business. Read the whole statement, both halves in one hand, and you see it for what it is: a real business, genuinely improving, that has not yet reached safe ground. The eight quarters of progress behind it are real. So are the doors still closed in front of it.

$IBRX Somewhere this week, an oncologist in Boston, or Munich, or Manchester is saying the same sentence to a lung cancer patient. Call him John. We have run out of options, the doctor tells him. The chemotherapy stopped working. Then the checkpoint immunotherapy, the standard kind that takes the brakes off the immune system, stopped working too. There is nothing standard left to try. And this same week, a government on the other side of the world approved the one thing John is not allowed to have. On July 29, the United Arab Emirates authorized ANKTIVA - an immune therapy that, in exactly the patients that oncologist just ran out of moves for, saw the typical patient live nearly 15 months, against the 7 to 9 that standard chemotherapy delivers. ANKTIVA is now approved for lung cancer in two countries on earth. Neither of them is the United States. Neither is in Europe. So here is what we are going to do, all of it in the open. First the map: who can get this drug, and who, despite needing it most, cannot. Then the arithmetic: what that access is actually worth, every number traceable and every assumption laid bare. Then the part almost no one prints, where the real price lands once you leave American list prices behind. And last, why every figure in here is only the floor of what this becomes. No hype, no price targets. Just the numbers, and where they point. THE BROADEST YES SO FAR First, what ANKTIVA is, in one line: it is not chemotherapy. It is an IL-15 signal, the body's own trigger for waking up the immune system's natural killer cells and T cells, the cells that do the actual killing of cancer. The United Arab Emirates did not just approve it. Its regulator, the Emirates Drug Establishment, approved the broadest label any regulator has granted so far, across two cancers at once: bladder cancer in patients who failed the standard BCG therapy, and metastatic lung cancer in patients who failed both chemotherapy and immunotherapy. And broadest is not a flourish. On the bladder side, the UAE cleared a group of patients no other regulator has cleared, the FDA included, which does not even rule on those same patients until January. Sit with that for a second: a small Gulf authority went further than the most powerful drug regulator on earth. We will come back to why that matters. That is not a company appearing from nowhere. It is the newest step in a march that is easy to miss one press release at a time: the United States first, in 2024. Then Britain, in 2025. Then Saudi Arabia, this January. Then the European Union, this February. Now the UAE, the fifth major regulator. Five of them, on three continents, in a little over two years, and ANKTIVA is now cleared in 34 countries. But a headline is not evidence. Before we map who is allowed to take it, the fair question is whether it is worth taking at all. WHY IT IS WORTH WANTING A drug is only worth fighting over if it works. Here is what the trials behind these approvals showed, the ANKTIVA numbers taken straight from the regulator's own review. In lung cancer, in patients who had already failed both chemotherapy and immunotherapy, adding ANKTIVA back onto the same immunotherapy they had failed produced a median survival of 14.6 months. Standard chemotherapy in that setting delivers about 7 to 9. In the patients whose immune systems rebuilt during treatment, survival reached 16.2 months. In bladder cancer, the numbers are the kind that change how a disease is treated. In the carcinoma in situ group, 71 percent of patients had their cancer completely disappear, and those responses proved durable: a median of more than two years, with the longest running past four and a half. In the papillary group, the one only the UAE has approved, 58 percent were still cancer-free at a year, and 83 percent still had their bladder at three. That last number is the human one. When bladder cancer stops responding to standard therapy, the textbook next step is cystectomy, surgically removing the bladder. This is a drug that, for most of these patients, kept the bladder in the body. For years, the choice these patients faced was a brutal one: lose the bladder, or run out of options. So it works. The next question is the one that turns a medical story into an injustice: who, exactly, is allowed to have it? Read the fine print, one indication at a time. WHERE YOU CAN ACTUALLY GET IT Bladder cancer comes in a few flavours, and the approvals split cleanly across them. Here is the real map. - The core bladder patient, carcinoma in situ (a flat, high-grade tumour) after BCG has failed: approved almost everywhere. United States, United Kingdom, the thirty countries of the EU and EEA, Saudi Arabia, and the UAE. On this one, the developed world is covered. - The next bladder group, papillary-only disease (the frond-shaped tumours, with no carcinoma in situ) after BCG has failed: approved in exactly one place on earth, the UAE. The United States has not ruled yet; its decision is due January 6, 2027. This is the single thing the UAE did that no one else, including the FDA, has done. - The largest bladder group of all, first-line patients newly diagnosed, before they have ever failed BCG: approved nowhere yet. The filing is expected in the last quarter of this year. - And lung cancer, metastatic, after chemotherapy and immunotherapy have both failed: approved in only two countries, Saudi Arabia and the UAE. Not the US. Not the UK. Not the EU. That last line is the whole story: the disease with the most patients by far is the one almost no one is allowed to treat with it. HOW MANY, REALLY Nobody publishes this number cleanly, so we built it: cancer-registry totals for each country, narrowed fraction by fraction with the published medical literature, every fraction sourced and every one carrying error. Treat each count below as an estimate with real margins, not a hard figure. For lung, the addressable patient is metastatic, and has already progressed after a checkpoint immunotherapy. Run the funnel and you get, per year, roughly: - United States: about 62,000 such patients. - European Union: about 73,000. - United Kingdom: about 11,500. - Saudi Arabia and the UAE combined: about 350. - The whole world: on the order of 590,000. The bladder numbers, by contrast, are small everywhere, because the approved bladder slices are narrow: a few thousand a year in the United States, several thousand across the European Union, and dozens, not thousands, in the Gulf. THE PRIZE IS LUNG, AND ALMOST NO ONE CAN GET IT Now put the map and the math together, and the picture is stark. For lung cancer, ANKTIVA is approved for roughly 350 patients a year, meaning the Saudi and UAE patients who reach this last-line stage, not their total lung caseload but the sliver who have exhausted everything else. Meanwhile, in the three places with the deepest pockets and the finest hospitals, the United States, the European Union, and the United Kingdom, there are about 146,500 of these patients a year. Every one of them is locked out, because the drug is not approved where they live. Three hundred and fifty approved. A hundred and forty-six thousand locked out in the wealthy world alone, and behind them almost the whole 590,000 worldwide. The rich-world number is not the whole injustice, just its sharpest edge: even the countries that can afford anything cannot buy a drug that is not approved. That is not access. It is a keyhole. The treatment, if the trials hold up, landed first in the one place almost no patient lives. NOW THE MONEY: THREE DOORS OPEN We would not turn patients into a revenue figure by guessing. So here is the opposite of a guess: a worked example, every input named and rounded, that you can push on. Treat all of it as deliberately, almost crudely approximate. The point is the shape, not the decimal. Because ANKTIVA for lung exists in only two countries, it opens three doors, not one. The first door is home. Saudi Arabia and the UAE have about 350 of these last-line lung patients a year, plus a few dozen on the bladder side, and their governments pay for their own citizens. Call it 400 people. The second door is the neighbours. The other Gulf states, Kuwait, Qatar, Oman, Bahrain, already spend billions flying their citizens abroad for care they cannot get at home; Kuwait alone sends hundreds of patients a month, with cancer near the top of the list. When the one drug a patient needs now sits in Riyadh or Abu Dhabi instead of Houston or Frankfurt, some of that sponsored flow turns toward the nearer door. Imagine 100 of them a year. The third door is private wealth, and here the limit is not really money. Plenty of families will sell a house to buy a parent another year; a few hundred thousand dollars, awful as that is, is not the wall. Three other things are. One is the medicine itself. This approval is for the last-line patient: metastatic, already failed both chemotherapy and immunotherapy, gaining months, not a cure. Many are simply too sick to fly across the world and back for a treatment given in repeated rounds. Two is knowing it exists at all. Most patients will never be told that an obscure drug approved in two countries is even an option. Whether that changes is a marketing question, how hard ImmunityBio and the Gulf decide to spread the word, and that we cannot see from here. Three is the American doctor. A US oncologist cannot bill for a drug that is not approved here, and earns nothing by sending a patient abroad, while the standard American options sit in the same clinic, reimbursed. We are not saying doctors put the invoice first. We are saying the incentive runs the other way, that behaviour varies, and that it quietly narrows the door. WHAT A YEAR COSTS, HONESTLY Now the price, and here is where you have to be honest with yourself. ANKTIVA's US list price works out to roughly 300,000 dollars for a year of treatment, but almost no one outside America pays an American list price. European governments pay something like half, sometimes a third, of the US price for cancer drugs, because they regulate what they will pay, and those prices drift down over the years rather than up. A Gulf government negotiates too, though as a smaller and wealthier buyer it may not squeeze as hard as price-regulated Europe. And Washington itself is now trying to drag US prices down toward the rest of the world's, under the same most-favoured-nation order that already made ImmunityBio pause its UK launch while it reworked the plan. So the real ex-US price sits well below the US sticker. Call it 200,000 dollars a patient for this example, below the American price but above Europe's deepest discounts, and know it could go lower still. TURN THE DIAL So how many patients actually walk through those doors? Nobody knows. Which is exactly why we will not hand you one number. We will hand you the dial. Start with the firm part: the two governments treating their own citizens, about 500 people across the domestic and sponsored doors. And remember why even that base is so small: it counts only the approved use, last-line, after everything else has failed, a fraction of the patients this drug is being tested to reach. Now add the fly-in patients on top, at that 200,000-dollar-a-year price, and watch it scale. - Cautious, 200 of them, about 700 patients in all: roughly 140 million dollars a year. - If word spreads, 500 of them, about 1,000 patients: roughly 200 million. - If it really moves, 1,000 of them, about 1,500 patients: roughly 300 million. Pick the rung you believe. Every extra hundred patients is another 20 million dollars at this price, and the inputs are all above, so if you think the real number is higher, run it yourself. TINY TO THE WORLD, THE SIZE OF THE COMPANY Now the two rulers, and they hold at every rung of that ladder. Against the disease, it still vanishes. Even the top of the range, 1,500 patients, is a quarter of one percent of the 590,000 who need this drug. On the scale of the illness, a rounding error. Against the company, it is the whole company, and at the top of the range more than double it. ImmunityBio's entire ANKTIVA revenue last year was about 113 million dollars. The cautious rung already sits on top of that; the higher rungs are multiples of it. In the one place on earth where the drug has no competitor, that is a second engine. AND FIRST-LINE CHANGES EVERYTHING Here is what makes every figure above a floor. All of it counts only the last-line patient, John at the start of this piece: the sickest, the least able to travel, the one gaining months. But ANKTIVA is in trials now to move earlier, to the first-line patient, who is stronger, far more numerous, and stands to gain far more. So go back in time with John. Picture him a year earlier, before the immunotherapy failed, while his immune system is still standing, and imagine this drug is offered to him then, first-line. His oncologist tells him the truth: in a small, early first-line trial, the average patient in his position lived about three years, against under two on what came before. An average is not a promise, and John knows it. But he also knows something about this kind of medicine. Chemotherapy gives almost everyone the same short window. Immune therapy does not. It has a tail, a slice of patients who get years, who are still here long after the curve said they would be gone. John cannot know if he is in that slice. What he knows is that chemotherapy never had a slice to be in. So he sells the house, and he goes. Multiply John by every family who will make that same bet once the drug is offered first, while there is still an immune system left to wake, and you have the day the arithmetic above stops being a floor and becomes a different number entirely. THE CATCH Now the limits, stated plainly, because a number without its caveats is a lie of omission. The lung survival result that started all of this comes from a single-arm study, meaning there was no built-in comparison group, so the comparison is to older trials, not a head-to-head. The larger, randomized confirmation is still enrolling. Every patient count above is a derived estimate, built by multiplying fractions, each carrying error, and the small-country figures carry the most. The dollar figure is rougher still, anchored to a US price that will not be the price in the Gulf. What is real is the disease itself: post-checkpoint lung cancer is a multi-billion-dollar unmet need by any measure, and today the drug reaches a keyhole of it. WHAT WE DID NOT COUNT Everything above counts only what is approved and countable today. None of the following upside is in the numbers, and any of it could change the picture. - Known and scheduled, not yet decided: first-line bladder, the largest bladder population of all, with a filing expected later this year. The papillary-only bladder decision at the FDA, due January 6, 2027. - Announced ambitions, unquantified: the push into Africa and global access, and the question of who ultimately pays for it. Real as a direction, zero as a counted number today. - In trials, no approvals yet: lung moving earlier into first-line, the rest of the basket of other solid tumours the drug is being tested in, and the non-cancer arms, restoring the immune system's depleted cells and sepsis. - Pure surprises: an unexpected accelerated approval, new clearances in Japan, Asia, Latin America, or more of the Gulf, or the lung approval spreading beyond Saudi Arabia and the UAE. Any of these can arrive without warning. So read every number here for exactly what it is: the floor. What is real, approved, and countable right now, with the upside named and deliberately set aside. If any of it lands, the picture only grows. ANKTIVA carried last-line lung cancer patients to nearly 15 months, where chemotherapy carries them 7 to 9. It is now approved on three continents. And almost none of the roughly 590,000 people who need it can get it, not in Boston, not in Munich, not in Manchester, not anywhere the map stays dark. One of them is John. The map exists. His address is not on it. Yet.